

Training Toolkit

HIV Care and Antiretroviral Treatment
Recording and Reporting System



**EXERCISE
BOOK**

2006



**World Health
Organization**

Regional Office for South-East Asia
New Delhi

Further publications can be obtained from the HIV/AIDS Unit,
Department of Communicable Diseases, World Health Organization,
Regional Office for South-East Asia, World Health House, Indraprastha Estate,
Mahatma Gandhi Road, New Delhi 110002, India.
Fax +91-11-23370197, 23379395, 23379507
Email: hiv@searo.who.int
Library support: library@searo.who.int

© World Health Organization 2006

Publications of the World Health Organization enjoy copyright protection in accordance with the provisions of Protocol 2 of the Universal Copyright Convention. For rights of reproduction or translation, in part or in toto, of publications issued by the WHO Regional Office for South-East Asia, application should be made to the Regional Office for South-East Asia, World Health House, Indraprastha Estate, New Delhi 110002, India.

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.

Designed and Printed in India by: Macro Graphics Pvt. Ltd., www.macrographics.com

Document No.: SEA/AIDS/161

ISBN No.: 92 9022 268.9

Exercise Book

HIV Care and ART Recording and Reporting System

Exercise 1 - Patient record & Pre-ART & ART Registers	1
Exercise 2 - Drug Dispensing and Stock Registers	19
Exercise 3 - Monthly report	35
Exercise 4 - Cohort report	55
Exercise 5 - Cohort interpretation	67

Exercise 1 – Patient record & Pre-ART & ART Registers

Refer to Participant Manual, module 2 and module 3

CASE STUDIES

This exercise will help you in understanding how to complete the patient record. The medical history of 2 patients is developed in 2 case studies.

Question 1: Read their medical history and complete their patient record accordingly.

Question 2: Refer to the patient records you have completed and complete the pre-ART and ART registers accordingly.

EXERCISE 1, CASE STUDY 1

A 28-year-old man, Mr A, came to your clinic (code AB) for the first time on February 4th 2004. He was the 2356th patient accessing your clinic according to the serial order.

He was tested HIV-positive when his wife was hospitalized and died from AIDS in March 2003. He also lost a HIV-positive child in 2003. He contracted HIV through heterosexual transmission. He has not remarried (and has no partner at this moment) and is taking care of a 2-year-old son who tested HIV negative and a 4-year-old daughter, not yet tested for HIV. He is not literate and is living with his parents in a small farm. Both his parents are aware of his HIV status and are supporting him. He is too weak for regular activity but participates as much as he can in activities at the farm. He came to the clinic himself after he heard on the radio that it was offering treatment for HIV infected people. He was never previously treated with antiretroviral drugs.

On February 4th 2004, he presented to the ART clinic with a wasting syndrome. His weight was 47 kg and said that he had lost a lot of weight. He was suffering from chronic diarrhoea of more than 3 months and presented with oral candidiasis. A blood sample was taken for CD4 count and he was prescribed cotrimoxazole primary prophylaxis and 7 days of fluconazole for oral candidiasis. He requested for HIV treatment and attended his first counselling session.

On February 18th 2004, he came on time for the scheduled appointment with his two children and his mother as requested by the counselling team. A voluntary counselling and testing was performed for the children and HIV tests performed for both were negative. During the second counselling session on antiretroviral treatment, he expressed his willingness to start and adhere to treatment. His mother agreed to support her son's treatment as much as possible by reminding him to take the pills. The CD4 results performed on February 4th showed 59 cells/mm³. Apart from the wasting syndrome, he was not suffering from any opportunistic infections, in particular he had no symptoms of TB. Cotrimoxazole prophylaxis was maintained. The next appointment was scheduled on March 1st 2004.

On March 1st 2004, he started D4T/3TC/NVP and continued cotrimoxazole. His weight was 46 kg. He visited the clinic for his next appointed visit on March 16th. He reported not having missed any doses of ART. He complained about nausea and abdominal pain when taking pills but these troubles were less important compared to the first days of treatment. His weight was 45 kg. NVP was prescribed at full dose in fixed dose combination with D4T/3TC, cotrimoxazole was maintained.

He returned for his next appointment on April 1st 2004 and reported not having missed any doses. He did not complain about digestive troubles. His weight was 45 kg. The same treatment was maintained and he was given another appointment on May 1st 2004.

On May 1st 2004, Mr A complained of asthenia, moderate fever in particular at night, and productive cough which started the week following his last visit. He lost appetite and his weight was 44 kg. He missed 5 pills of ARV due to vomiting. You maintained the same treatment and referred him to the TB clinic.

Smear examination results were positive for TB. On May 5th, during a control visit you stopped ARV regimen and started TB regimen (HRZE) prescribed at the TB clinic. You maintained

cotrimoxazole primary prophylaxis. Mr A is appointed for DOTS follow-up at the TB clinic and you asked him to come to your clinic in one month on June 5th 2004.

As of June 5th 2004, the TB treatment was well tolerated. There were no signs of hepatotoxicity. His weight was 45 kg. As the patient has Stage IV AIDS and low CD4 count, you preferred not to delay ART any more and you decided to restart, substituting NVP for EFV. You prescribed D4T/3TC in FDC and EFV.

On the next appointed visit on July 5th, the TB and ARV treatment were well-tolerated without any signs of hepatotoxicity. An examination of sputum smear was negative. After consultation with the TB clinic, it was decided to continue isoniazide and rifampicin for the continuation phase of TB treatment. Mr A reported not having missed any pills of ARV. His weight was 46 kg. No other opportunistic infections were diagnosed and Mr A was getting better.

On the next appointed visit on August 5th, the TB and ARV treatment were still well-tolerated without any signs of hepatotoxicity. He reported not having missed any pills of ARV. His weight was 48 kg. No opportunistic infections were diagnosed. You intensified counselling regarding prevention and care and gave him adequate number of condoms.

On September 8th 2004, Mr A came 3 days later for his appointed visit of September 5th. He reported having started again activities at the farm and was busy finding an employment. He missed one full day of ARV (2 doses) because of this delay. The TB and ARV treatment were well tolerated without any signs of hepatotoxicity. His weight was 51 kg. No opportunistic infections were diagnosed. You took a blood sample for CD4 count at 6 months. You continued the same treatment and insisted on respecting the scheduled visits to avoid any discontinuation in treatment. You gave him an extra drug stock for one week to avoid any discontinuation of ART. You also intensified counselling on prevention and gave him a stock of condoms.

On October 8th 2004, Mr A came on time for his appointed visit. He reported not having missed any ART doses. The TB and ARV treatment were well-tolerated without any signs of hepatotoxicity. His weight was 52 kg. No opportunistic infections were diagnosed. The CD4 count performed during the previous visit showed 119 CD4 cells/mm³. Mr A said that he had found a daily wage employment in addition to the work at the farm.

During the visit on November 8th (as scheduled) the treatment for TB was completed and stopped. The ART was well-tolerated and Mr A reported not having missed doses. His weight was 53 kg and Mr A said he had almost the same body shape as before the time he was sick. You intensify counselling on prevention and gave him adequate number of condoms.

On December 8th, Mr A came on time for monthly follow-up. He did not miss any doses. He informed you that the family had decided to move to his sister's house in the neighbouring province capital, as his sister's husband had offered him a permanent job. He asked if it was possible to follow-up treatment in that city. You contacted your colleagues from the HIV care/ART management team in that city (clinic code XE) and decided to transfer the patient with an appointment scheduled after one month on January 8th 2005. You gave him a copy of his medical file as well as a letter for your colleagues, and all contact information to be given to the new clinic. You prescribed the same treatment (D4T/3TC (FDC) + EFV and cotrimoxazole primary prophylaxis) for this last month of follow-up at your clinic

(To be stored in a locked cabinet at the health centre and arranged serially by registration number)

* Performance scale: A- Normal activity; B- bedridden <50% of the day during last month; C- bedridden > 50% of the day during last month

4

EXERCISE 1, CASE STUDY 2

A 25-year-old woman, Mrs Y, came to clinic AB for the first time on 21st August 2003, referred by the Mother and Child (MCH) Clinic. She was the 1508th patient registered at clinic AB.

She is the spouse of Mr Y, a 31-year-old patient regularly followed-up at clinic AB (ID number: AB-0186). She was tested HIV-positive during voluntary counselling and testing (VCT) for pregnancy in January 2003 at the MCH clinic, and the mother and baby (a little girl born on February 15th 2003) were treated by a single dose nevirapine. She did not breastfeed. Following delivery, her husband accepted VCT couple counselling and was found to be HIV-positive. He went to clinic AB and started ART in July 2003. Mrs Y being asymptomatic delayed her first visit to clinic AB. She is a teacher, a graduate from the University. She is well informed regarding HIV/AIDS. She has no personal risk factor. The baby is doing fine, and being regularly followed-up at the MCH clinic (ID number MC-0023).

On 21st August 2003, Mrs Y was asymptomatic. Her weight was 58 kg. The total lymphocyte count was 1600 cells/mm³. She was using an oral contraceptive method. You discussed a mid-term follow-up and gave her an appointment in 6 months and asked her to come earlier in case of any clinical symptoms.

On 21st March 2004, she returned for the appointed visit. She presented with seborrheic dermatitis of a few weeks. You noticed that she had lost weight and was now 55 kg. Baseline TLC was 1600 cells/mm³. She said her baby was tested and found HIV negative by rapid test at 12 months. You insisted on more regular visits and she was asked to visit every 3 months as she was very busy. She was given an appointment for 21st June 2004.

Mrs Y came earlier than her appointed visit, on 2nd May 2004, as she had oral thrush. Her weight was 53 kg. You prescribed fluconazole and started cotrimoxazole primary prophylaxis. A blood sample was taken for baseline CD4 count and the next appointed visit was after a month. She is still working but has reduced her activities a lot.

On 2nd June 2004, Mrs Y came on time. Her weight was 51 kg and she complained about frequent and intermittent diarrhoea. Oral thrush was cured. The CD4 result was 190 cells/mm³ and you discussed about starting ART. A first counselling session was performed and an appointment given in 2 weeks. Cotrimoxazole was continued.

On 17th June 2004, Mrs Y came on time. Diarrhoea was more frequent and her weight was 50 kg. After a second treatment counselling, you decided to start D4T/3TC/NEV. Mrs Y was still using an oral contraceptive method. An appointment was given in 2 weeks.

On 22nd June 2004, Mrs Y came without appointment as she presented with moderate pruriginous cutaneous rash. You substituted NEV for EFV and informed her regarding the risk of pregnancy. You also stopped cotrimoxazole. You asked her to come in a week.

On 29th June 2004, Mrs Y came on time. The rash had disappeared and the new treatment was well tolerated. She did not miss any doses. Her weight was 50 kg. Mrs Y still complained of episodes of diarrhoea. An appointment was scheduled in one month.

On 29th July 2004, Mrs Y came on time. The treatment was well tolerated and she reported not having missed any pills. Her weight was 52 kg. Episodes of diarrhoea had stopped almost two weeks earlier. She said that an HIV test at 18 months was negative for her baby.

On 12th September, Mrs Y was 13 days late for her appointment and missed almost 13 days of treatment. She had been travelling with her family due to family problems and had to stay away longer than planned. She was not able to find ART to continue her treatment. There were no symptoms and her weight was 52 kg. You intensified counselling on adherence. You also restarted cotrimoxazole but asked her to stop it immediately and come to the clinic if she developed a rash. She was still under oral contraceptives.

On 12th October 2004, Mrs Y came on time. She reported having missed two days of ART (4 doses), because she was travelling and forgot to carry her pills. Her weight was 54 kg. You intensified counselling on adherence and asked the presence of her husband as support. Mrs Y reported that she now had the same activity levels as before she became sick.

On her next appointed visit on 12th November 2004, Mrs Y came on time. She did not miss any doses. Her weight was 56 kg.

On her next appointed visit on 12th December 2004, Mrs Y came on time. She did not miss any doses. A blood sample collected on 30th November for CD4 count showed 245 cells/mm³. Her weight was 58 kg. Her next appointment was given after 1 month.

Question 1: Complete the Patient HIV Care and Antiretroviral Treatment (ART) Record

(To be stored in a locked cabinet at the health centre and arranged serially by registration number)

Answer sheet exercise 1 question 1

1. Patient Identification Data
 (Write complete information)

Registration Number :

code clinic (2#)-code patient (4#)

Name of Treatment Unit:

City:

District:

State/province:

Name of patient:

Sex:

Male
 Female

Age:

date of birth:

dd / mm / yy

Patient's phone number:

Address:

City/village:

District:

State/province:

Distance from residence to clinic (km)

Treatment supporter's name (if applicable)

Treatment supporter's address:

Treatment supporter's phone number:

Place:

Date confirmed HIV+ test:

dd / mm / yy

Entry point (services referring the patient for HIV care):

1-VCT
 2-TB
 3-Outpatient
 4-Inpatient
 5-Paediatric
 6-PMTCT
 7-STI
 8-Private
 9-NGO
 10-Self referred
 11-IDU outreach
 12- CSW outreach
 13-other

patient transferred in on ART from another HIV care/ART clinic from the national program

Name previous clinic:

Date transferred in :

2. Personal History
 (Tick one choice)

Mode of HIV trans- mission

1 Commercial sex worker (CSW)
 2 Other heterosexual route
 3 Men having sex with men (MSM)
 4 Injecting drug use (IDU)
 5 Blood transfusion
 6 Mother to child
 7 Unknown

For IDUs

Substitution therapy
 Y
 N

If yes, type:

Literate
 Yes
 No

Employed

Yes
 No

Alcoholism

Habitual
 Social
 No use

3. Family History
 (Tick one choice)

Marital status:

Single
 Married
 Divorce/separate
 Widowed
 Not applicable

Estimated monthly household income:

Family members:

partner/children
 Age/sex
 HIV +/-unknown

ART Y/N

Regist. No if in care

4. Antiretroviral treatment history

Was ART received before?

Yes
 No

If yes

PMTCT
 Earlier ART

Place:

Private
 Govt

Drugs and duration:

5. Clinical and Laboratory Investigations

Date (dd/mm/yy)

WHO stage

Weight (kg)

Height (cm)

Perfor- mance A/B/C*

Total lymphocyte count

CD4 count (or % in children)

At 1st visit in clinic

At ART medical eligibility

At start of ART

At 6 months ART

At 12 months ART

At 24 months ART

6. Antiretroviral Treatment

Treatment Started

SUBSTITUTION within 1st line, SWITCH to 2nd line, STOP, RESTART

D4T30+3TC+NVP

D4T40+3TC+NVP

D4T30+3TC+EFV

D4T40+3TC+EFV

ZDV+3TC+NVP

ZDV+3TC+EFV

Date

Substitution, switch or stop

Reason (code)

Date restart

New regimen

Reasons SUBSTITUTE: 1 toxicity side effects, 2 pregnancy, 3 risk of pregnancy, 4 newly diagnosed TB, 5 new drug available, 6 drug out of stock, 7 other reason (specify)

Reasons for SWITCH: 1 clinical treatment failure, 2 immunological failure, 3 virologic failure

Reasons STOP: 1 toxicity side effects, 2 pregnancy, 3 treatment failure, 4 poor adherence, 5 illness hospitalization, 6 drug out of stock, 7 patient lack of finance, 8 patient decision, 9 planned treatment interruption, 10 others

7. Tuberculosis treatment during HIV care

Disease class (tick)

Pulmonary TB
 Smear-positive
 Smear-negative
 Extrapulmonary

TB Regimen (tick)

Category I
 Category II
 Other specify:

TB registration

District:
 Health Centre:
 TB number:

Treatment outcome:

Cure
 Rx completed
 Rx failure
 Died
 Default
 Transfer out

Date:

dd / mm / yy

Date start TB Rx:

dd / mm / yy

8. End of Follow-up

Death

Lost to follow-up (>3 months)

Transferred out

Date of death:

dd / mm / yy

Date last visit:

dd / mm / yy

Date:

dd / mm / yy

New clinic:

* Performance scale: A- Normal activity; B- bedridden <50% of the day during last month; C- bedridden > 50% of the day during last month

Question 2: according to the information you have recorded in the patient record, complete the pre-ART and the ART registers for the 2 case studies.

Answer sheet exercise 1 question 2: pre-ART register

HIV CARE - PRE ART REGISTER: Fill at first visit column 1 to 10										Fill when applicable column 11 to 16							
1	2	3	4	5	6		7	8	9	10	11	12	13	14	15	16	
DATE 1st visit at the clinic	Registration number	Patient's name and address	Age	Sex M/ F	Confirmed HIV+ test		Entry point - code 1 to 13*	risk factor - code 1 to 7**	Literate	Employed	CPT Date of Start	TB treatment Class/Regimen Date of start	DATE medically eligible for ART	Why medically eligible?	DATE ART started	End of follow-up before starting Date lost to FU (last transferred out visit)	Date transferred out
1									☐ Y ☐ N	☐ Y ☐ N				Who stage Cdd4 #/% TLC#			
2									☐ Y ☐ N	☐ Y ☐ N				Who stage Cdd4 #/% TLC#			
3									☐ Y ☐ N	☐ Y ☐ N				Who stage Cdd4 #/% TLC#			

*Entry point: 1-VCT; 2-TB; 3-Outpatient; 4-Inpatient; 5-Paediatric; 6-PMTCT; 7-STI; 8-Private; 9-NGO; 10-Self referred; 11-IDU outreach; 12- CSW outreach; 13-other - Write code TR if the patient was transferred in on ART

**Mode of HIV transmission: 1-Commercial sex worker (CSW), 2-Other heterosexual route, 3-Men having sex with men (MSM), 4-Injecting drug use (IDU), 5-Blood transfusion, 6-Mother to child, 7-Unknown

CPT: Cotrimoxazole preventive therapy

DATE of start of ART	Registration number	Patient's first name and surname	Age	Sex M/ F	Patient's address and contact number	Treatment supporter's name and contact number	Prior ARV history	WHO stage at start of Rx	Performance scale A-normal activity; B-bedridden<50%; C-Bedridden>50%	Weight (kg) at start, 6, 12, 24 months of ART	CD4 count at start, 6, 12, 24 months of ART (absolute number for adults and % for children)	TB treatment during ART Disease, Category Regimen Date Rx Start	ART regimen started
1							☐ Y ☐ N	At start of Rx At 6 months At 12 months At 24 months	At start of Rx At 6 months At 12 months At 24 months	At start of Rx At 6 months At 12 months At 24 months	At start of Rx At 6 months At 12 months At 24 months		
2							☐ Y ☐ N	At start of Rx At 6 months At 12 months At 24 months	At start of Rx At 6 months At 12 months At 24 months	At start of Rx At 6 months At 12 months At 24 months	At start of Rx At 6 months At 12 months At 24 months		
3							☐ Y ☐ N	At start of Rx At 6 months At 12 months At 24 months	At start of Rx At 6 months At 12 months At 24 months	At start of Rx At 6 months At 12 months At 24 months	At start of Rx At 6 months At 12 months At 24 months		

ART register continued

Treatment substituted within 1st line drugs				Treatment switched to 2nd line			End of follow-up on ART		Monthly visits: • 1st row: write patient outcome • 2nd row: write adherence (see ART register form)													
Date substituted	Reason*	New Regimen	Date switched	Reason**	New Regimen	Date of death	Date lost to FU (last visit)	Date transferred Out on ART	Week 2	mo. 1	mo. 2	mo. 3	mo. 4	mo. 5	mo. 6	mo. 7	mo. 8	mo. 9	mo. 10	mo. 11	mo. 12	mo. 13

* Reasons for substitution within first line treatment1-toxicity or side effects; 2-pregnancy;3-risk of pregnancy; 4-newly diagnosed TB; 5-new drug available; 6-drug out of stock; 7-other reason.

** Reasons for switching to second line treatment1-toxicity or side effects; 2-pregnancy; 3-risk of pregnancy; 4-newly diagnosed TB; 5-new drug available; 6-drug out of stock; 7-other reason; 8-clinical treatment

Reasons for stopping ART: 1- toxicity side effects; 2-pregnancy; 3-treatment failure; 4-poor adherence; 5-illness hospitalisation; 6-drug out of stock; 7-lack of finance; 8-patient's decision to stop; 9 other reason.

Exercise 2- Drug Dispensing and Stock Registers

Refer to Participant Manual – Module 4

This exercise will help you in understanding how to maintain the drug dispensing and the drug stock registers, and how to transfer this information in the monthly report at the end of the month.

Clinic A is open twice a week. On 31 June 2005, Clinic A had the following stock of drugs (number of tablets):

◆ Stavudine 30 / Lamivudine / Nevirapine	5800
◆ Stavudine 40 / Lamivudine / Nevirapine	2500
◆ ZDV+3TC	2000
◆ Stavudine 30 / Lamivudine	500
◆ Stavudine 40 / Lamivudine	100
◆ Nevirapine	600
◆ Efavirenz	500

On 20/7/2005, clinic A received a stock of Stavudine 30 / Lamivudine / Nevirapine (5000 pills) and Stavudine 40 / Lamivudine / Nevirapine (2000 pills).

The stock of Stavudine40 /Lamivudine (100 pills) will expire on 20/7/2005.

During the month of July 2005, the patients coming to the clinic to pick up their drugs were recorded daily in the drug dispensing register by the pharmacist, presented in the following pages.

Refer to this drug dispensing register for the drugs dispensed during the month of July 2005.

1. Complete the total of tablets dispensed for each drug every day in the drug dispensing register
2. Update the drug stock register for the month of July 2005.
3. Complete sections 11 and 12 of the ART Monthly Report
4. How many patients picked up their drugs in July?
5. Which drugs and what amount need to be ordered for the next quarter?
6. As a ART manager, how will you act based on the monthly report?

Drug Dispensing Register Clinic A

Question 1: Complete the total of tablets dispensed for each drug every day

Exercise 2- Drug Dispensing and Stock Registers

Date: 04 / 07 / 05

SI No.	Patient Name	d4T30/3TC/ NVP	d4T40/3TC/ NVP	ZDV/3TC	d4T30/3TC	d4T40/3TC	Nevirapine	Efavirenz	Remarks	Patient Signature
1.	ACV	60								ACV
2.	New 1				30		15			NEW 1
3.	XTD	60								XTD
4.	XYZ			60			60			XYZ
5.	ERT		60							ERT
6.	QWE	60								QWE
7.	ASD	60								ASD
Total tablets Dispensed										

Date: 06 / 07 / 05

SI No.	Patient Name	d4T30/3TC/ NVP	d4T40/3TC/ NVP	ZDV/3TC	d4T30/3TC	d4T40/3TC	Nevirapine	Efavirenz	Remarks	Patient Signature
1.	XCV	60								XCV
2.	RTY		60							RTY
3.	YUI			60			60			SDF
4.	SDF	60								XYZ
5.	UIO				60			30		UIO
6.	GFD	60								GFD
7.	GHJ	60								GHJ
8.	MNB	60								MNB
Total tablets Dispensed										

Date: 11 / 07 / 05

SI No.	Patient Name	d4T30/3TC/ NVP	d4T40/3TC/ NVP	ZDV/3TC	d4T30/3TC	d4T40/3TC	Nevirapine	Efavirenz	Remarks	Patient Signature
1.	ADF	60								ADF
2.	TYU	60								TYU
3.	KJH				60		60			KJH
4.	BVC	60								BVC
5.	DFS	60								DFS
Total tablets Dispensed										

Date: 13 / 07 / 05

SI No.	Patient Name	d4T30/3TC/ NVP	d4T40/3TC/ NVP	ZDV/3TC	d4T30/3TC	d4T40/3TC	Nevirapine	Efavirenz	Remarks	Patient Signature
1.	FTH	60								FTH
2.	DRG	60								DRG
3.	SEF				60			30		SEF
4.	KUY		60							KUY
Total tablets Dispensed										

Exercise 2- Drug Dispensing and Stock Registers

Date: 18 / 07 / 05

SI No.	Patient Name	d4T30/3TC/ NVP	d4T40/3TC/ NVP	ZDV/3TC	d4T30/3TC	d4T40/3TC	Nevirapine	Efavirenz	Remarks	Patient Signature
1.	VFE	60								VFE
2.	BGT	60								BGT
3.	NGY		60							NGY
4.	NEW 1	60								NEW 1
5.	PWE				60			30		PWE
Total tablets Dispensed										

Date: 20 / 07 / 05

SI No.	Patient Name	d4T30/3TC/ NVP	d4T40/3TC/ NVP	ZDV/3TC	d4T30/3TC	d4T40/3TC	Nevirapine	Efavirenz	Remarks	Patient Signature
1.	NEW 2				30		15			NEW 2
2.	GHJ	60								Ghj
3.	ZBV		60							zbv
4.	KAL			60			60			KAL
5.	GHI	60								Ghi
Total tablets Dispensed										

Date: 25 / 07 / 05

SI No.	Patient Name	d4T30/3TC/ NVP	d4T40/3TC/ NVP	ZDV/3TC	d4T30/3TC	d4T40/3TC	Nevirapine	Efavirenz	Remarks	Patient Signature
1.	ZDI	60								ZDI
2.	QRL		60							QRL
3.	MNO	60								MNO
4.	PQR			60			60			PQR
5.	TSR				60			30		TSR
Total tablets Dispensed										

Date: 27 / 07 / 05

SI No.	Patient Name	d4T30/3TC/ NVP	d4T40/3TC/ NVP	ZDV/3TC	d4T30/3TC	d4T40/3TC	Nevirapine	Efavirenz	Remarks	Patient Signature
1.	KRS			30			15			KRS
2.	TUV	60								TUV
3.	LMN	60								LMN
Total tablets Dispensed										

Drug Stock Register Clinic A

Question 2: Update the drug stock register for the month of July 2005

Answer sheet exercise 2 question 2

Name of the drug d4T30 / 3TC / NVP

	A	B	C	D	E	F	
Date	Opening stock	Stock received	Stock dispensed during month	Stock expired / discarded	Balance stock	Stock returned from patients* (death / non adher.)	Remarks

Monthly summary:

Stock at the start of the month / Opening stock (A):

Stock received during the month (B):

Stock at the end of month (E) = (A+B) - (C+D):

Stock dispensed during the month (C):

Stock expired/discarded during the month (D):

Name of the drug d4T40 / 3TC / NVP

	A	B	C	D	E	F	
Date	Opening stock	Stock received	Stock dispensed during month	Stock expired / discarded	Balance stock	Stock returned from patients* (death / non adher.)	Remarks

Monthly summary:

Stock at the start of the month / Opening stock (A):

Stock received during the month (B):

Stock at the end of month (E) = (A+B) - (C+D):

Stock dispensed during the month (C):

Stock expired/discarded during the month (D):

Name of the drug d4T30 / 3TC

	A	B	C	D	E	F	
Date	Opening stock	Stock received	Stock dispensed during month	Stock expired / discarded	Balance stock	Stock returned from patients* (death / non adher.)	Remarks

Monthly summary:

Stock at the start of the month / Opening stock (A):

Stock received during the month (B):

Stock at the end of month (E) = (A+B) - (C+D):

Stock dispensed during the month (C):

Stock expired/discarded during the month (D):

Name of the drug d4T40 / 3TC

	A	B	C	D	E	F	
Date	Opening stock	Stock received	Stock dispensed during month	Stock expired / discarded	Balance stock	Stock returned from patients* (death / non adher.)	Remarks

Monthly summary:

Stock at the start of the month / Opening stock (A):

Stock received during the month (B):

Stock at the end of month (E) = (A+B)- C+D):

Stock dispensed during the month (C):

Stock expired/discarded during the month (D):

Exercise 2- Drug Dispensing and Stock Registers

Name of the drug ZDV / 3TC

	A	B	C	D	E	F	
Date	Opening stock	Stock received	Stock dispensed during month	Stock expired / discarded	Balance stock	Stock returned from patients* (death / non adher.)	Remarks

Monthly summary:

Stock at the start of the month / Opening stock (A):

Stock received during the month (B):

Stock at the end of month (E) = (A+B) - (C+D):

Stock dispensed during the month (C):

Stock expired/discarded during the month (D):

Name of the drug NVP

	A	B	C	D	E	F	
Date	Opening stock	Stock received	Stock dispensed during month	Stock expired / discarded	Balance stock	Stock returned from patients* (death / non adher.)	Remarks

Monthly summary:

Stock at the start of the month/Opening stock (A):

Stock received during the month (B):

Stock at the end of month (E) = (A+B)-(C+D):

Stock dispensed during the month (C):

Stock expired/discarded during the month (D):

Name of the drug EFV

	A	B	C	D	E	F	
Date	Opening stock	Stock received	Stock dispensed during month	Stock expired / discarded	Balance stock	Stock returned from patients* (death / non adher.)	Remarks

Monthly summary:

Stock at the start of the month / Opening stock (A):

Stock received during the month (B):

Stock at the end of month (E) = (A+B) - (C+D):

Stock dispensed during the month (C):

Stock expired/discarded during the month (D):

Question 3: Complete sections 11 and 12 of the ART Monthly Report

- ◆ Question 4: How many patients picked up their drugs in July?
- ◆ Question 5: Which drugs and what amount need to be ordered for a stock of at least 3 months based on the existing number of patients?
- ◆ Question 6: As a ART manager, how will you act based on the monthly report?

Answer sheet exercise 2 question 3 to 6

11. REGIMENS AT THE END OF THE MONTH	
Regimen	No. of patients on ART
D4T30/3TC/NEV	
D4T40/3TC/NEV	
ZDV/3TC/NEV	
ZDV/3TC/EFV	
D4T30/3TC/EFV	
D4T40/3TC/EFV	
Total= No. of patients on ART at the end of this month (=9.5)	

12. DRUG STOCKS		
Was there a stock-out of antiretroviral drugs this month?	Yes ☐	No ☐
Was there a stock-out of drugs for opportunistic infection this month?	Yes ☐	No ☐

Name of the drug (list ARV and OI drugs)	Stock at the start of the month (A)	Stock received during the month (B)	Stock dispensed during the month (C)	Stock expired/ discarded during the month (D)	Stock at the end of the month (A+B)-(C+D)	Amount requested

Exercise 3- Monthly report

Refer to Participant Manual - Module 5

This exercise will help you in compiling a monthly report with the documents necessary. Using the last monthly report, the pre-ART and the ART registers, you will have to complete the new monthly report.

Clinic CL started offering HIV care and ART on 1st October 2004. We are now at the end of January 2005 and you are compiling the statistics for the monthly HIV care and ART report.

The documents available to do this report are:

- ◆ The Pre-ART Register;
- ◆ The ART Register;
- ◆ The report from December 2004.

Complete Parts 6 to 10 of the January 2005 ART Monthly Report. You can also use the ART Register to check the number of regimen dispensed and complete Part 11.

**Pre-ART Register
Clinic CL**

HIV CARE- PRE ART REGISTER: Fill at first visit column 1 to 10																Fill when applicable column 11 to 16				
DATE 1 st visit at the clinic	Registra-tion number	Name/ address	Age	Sex M/ F	Confirmed HIV+ test		Entry point code1 to 11*	risk factor code1 to 7**	Literate	Employed	CPT date start	TB treat. Class Regimen date start	DATE medical eligible for ART	Why medical eligible?	DATE ART started	End of follow-up before ART				
					Date	Place										Date of death	Date lost to FU (last visit)			
1 2/10/04	CL-0001		26	M	15/9/04		1	1	☒ Y ☐ N	☒ Y ☐ N	2/12/04			WHO stage CD4 #/% TLC#						
2 2/10/04	CL-0002		36	M	8/1/03		4	1	☒ Y ☐ N	☐ Y ☒ N	2/10/04		2/10/04	WHO stage: 4 CD4 #/%: 59 TLC#	15/10/04					
3 3/10/04	CL-0003		24	F	1/8/04		2	1	☐ Y ☒ N	☐ Y ☒ N	3/10/04	TB smear+ Regimen I 15/7/04	3/10/04	WHO stage: 3 CD4 #/% : 168 TLC#	28/10/04					
4 5/10/04	CL-0004		29	M	1/5/04		7	1	☐ Y ☒ N	☒ Y ☐ N	5/11/04			WHO stage CD4 #/% TLC#						
5 9/10/04	CL-0005		18	M	8/12/03		10	1	☒ Y ☐ N	☒ Y ☐ N	9/10/04		15/11/04	WHO stage: 3 CD4 #/%: 140 TLC#	15/12/04					
6 9/10/04	CL-0006		32	F	1/10/04		1	1	☐ Y ☒ N	☐ Y ☒ N	9/10/04		9/10/04	WHO stage: 4 CD4 #/% TLC#: 800	26/10/04					
7 11/10/04	CL-0007		45	F	20/9/04		1	1	☒ Y ☐ N	☒ Y ☐ N	11/11/04		11/12/04	WHO stage: 3 CD4 #/% TLC#: 1000	2/1/05					
8 12/10/04	CL-0008		24	M	2/10/04		1	1	☐ Y ☒ N	☒ Y ☐ N	12/12/04			WHO stage CD4 #/% TLC#						
9 12/10/04	CL-0009		23	F	2/10/04		1	1	☐ Y ☒ N	☐ Y ☒ N	12/11/04		20/1/05	WHO stage: 3 CD4 #/%: 121 TLC#						
10 15/10/04	CL-0010		32	F	6/5/03		10	3	☐ Y ☒ N	☐ Y ☒ N	15/10/04		15/10/04	WHO stage: 4 CD4 #/%: 148 TLC#	1/11/04					
11 16/10/04	CL-0011		29	M	4/10/04		4	1	☒ Y ☐ N	☐ Y ☒ N	16/10/04		16/10/04	WHO stage: 4 CD4 #/%: 26 TLC#	31/10/04					
12 18/10/04	CL-0012		22	M	3/10/04		1	1	☒ Y ☐ N	☐ Y ☒ N	18/10/04		18/12/04	WHO stage: 4 CD4 #/%: 79 TLC#	7/1/05					
13 20/10/04	CL-0013		30	F	5/9/04		1	1	☐ Y ☒ N	☒ Y ☐ N	20/11/04			WHO stage CD4 #/% TLC#						
14 23/10/04	CL-0014		36	M	10/2/04		8	1	☒ Y ☐ N	☐ Y ☒ N	23/10/04		23/10/04	WHO stage: 4 CD4 #/% TLC#	7/11/04					
15 26/10/04	CL-0015		45	M	5/9/04		1	1	☒ Y ☐ N	☒ Y ☐ N				WHO stage CD4 #/% TLC#						

*Entry point: 1-VCT; 2-TB; 3-Outpatient; 4-Inpatient; 5-Paediatric; 6-PMCT; 7-STI; 8-Private; 9-NGO; 10-Self referred; 11-IDU outreach; 12-SW outreach; 13-other - TR if transf

**Risk factor for HIV: 1-Heterosexual; 2-Men who have sex with men; 3-Sex work; 4-Injecting drug use; 5- Blood transfusion; 6-Mother to child; 7-unknown

CPT: Cotrimoxazole preventive therapy

HIV CARE- PRE ART REGISTER: Fill at first visit column 1 to 10																Fill when applicable column 11 to 16			
1	2	3	4	5	6		7	8	9	10	11	12	13	14	15	16			
DATE 1 st visit at the clinic	Registra-tion number	Name/ address	Age	Sex M/ F	Confirmed HIV+ test		Entry point code1 to 11*	risk factor code1 to 7**	Literate	Employed	CPT date start	TB treat. Class Regimen date start	DATE medical eligible for ART	Why medical eligible?	DATE ART started	End of follow-up before ART			
					Date	Place										Date lost to FU (last visit)			
1	26/10/04	CL-0016	26	M	12/10/04		3	1	☒ Y ☐ N	☒ Y ☐ N	26/10/04		26/10/04	WHO stage: 3 CD4 #%: 91 TLC#	15/11/04				
2	27/10/04	CL-0017	36	F	6/5/01		4	1	☒ Y ☐ N	☐ Y ☒ N	27/10/04		27/10/04	WHO stage: 4 CD4 #%: 14 TLC#	15/11/04				
3	NOVEMBER 2004																		
4	2/11/04	CL-0018	28	M	12/10/04		1	1	☐ Y ☒ N	☒ Y ☐ N	2/11/04		2/11/04	WHO stage: 4 CD4 #% TLC#	6/12/04				
5	2/11/04	CL-0019	25	F	12/10/04		1	1	☒ Y ☐ N	☒ Y ☐ N	3/1/05			WHO stage CD4 #% TLC#					
6	2/11/04	CL-0020	5	M	12/10/04		9	6	☐ Y ☒ N	☐ Y ☒ N	2/11/04		20/1/05	WHO stage: 3 CD4 #%: 9% TLC#					
7	2/11/04	CL-0021	3	F	12/10/04		1	6	☐ Y ☒ N	☐ Y ☒ N	2/11/04		25/11/04	WHO stage: 3 CD4 #%: 8% TLC#	20/12/04				
8	6/11/04	CL-0022	51	M	2/11/04		1	1	☐ Y ☒ N	☒ Y ☐ N	6/11/04		6/11/04	WHO stage:4 CD4 #%:38 TLC#	18/11/04				
9	6/11/04	CL-0023	24	M	2/9/04		7	1	☐ Y ☒ N	☐ Y ☒ N	6/12/04			WHO stage CD4 #% TLC#					
10	7/11/04	CL-0024	29	M	15/9/04		3	2	☒ Y ☐ N	☒ Y ☐ N	7/11/04		7/12/04	WHO stage: 3 CD4 #%: 180 TLC#	22/12/04				
11	11/11/04	CL-0025	32	F	9/6/04		2	1	☒ Y ☐ N	☐ Y ☒ N	9/6/04	TB smear + Regimen II 12/4/04	11/11/04	WHO stage:4 CD4 #%: 96 TLC#	26/11/04				
12	13/11/04	CL-0026	37	M	8/9/04		1	1	☒ Y ☐ N	☐ Y ☒ N	13/11/04		13/11/04	WHO stage: 4 CD4 #% TLC#	18/11/04				
13	15/11/04	CL-0027	20	F	15/6/04		10	1	☐ Y ☒ N	☒ Y ☐ N	15/11/04			WHO stage CD4 #% TLC#					
14	18/11/04	CL-0028	18	M	1/10/04		1	4	☐ Y ☒ N	☒ Y ☐ N	18/12/04			WHO stage CD4 #% TLC#					
15	18/11/04	CL-0029	27	M	1/11/04		1	1	☒ Y ☐ N	☒ Y ☐ N				WHO stage CD4 #% TLC#					

*Entry point: 1-VCT; 2-TB; 3-Outpatient; 4-Inpatient; 5-Paediatric; 6-PMTCT; 7-STI; 8-Private; 9-NGO; 10-Self referred; 11-IDU outreach; 12- SW outreach; 13-other - **TR if transf**
 **Risk factor for HIV: 1-Heterosexual; 2-Men who have sex with men; 3-Sex work; 4-Injecting drug use; 5- Blood transfusion; 6-Mother to child; 7-unknown
 CPT: Cotrimoxazole preventive therapy

HIV CARE- PRE ART REGISTER: Fill at first visit column 1 to 10																Fill when applicable column 11 to 16				
1	2	3	4	5	6		7	8	9	10	11	12	13	14	15	16				
DATE 1 st visit at the clinic	Registra-tion number	Name/ address	Age	Sex M/ F	Confirmed HIV+ test	Entry point code1 to 11*	risk factor code1 to 7**	Literate	Employed	CPT date start	TB treat. Class Regimen date start	DATE medical eligible for ART	Why medical eligible?	DATE ART started	Date of death	Date lost to FU (last visit)	Date transfer . out			
				Date														Place		
1	19/11/04	CL-0030	22	F	15/9/04	1	1	☒ Y ☐ N	☒ Y ☐ N	19/12/04			WHO stage CD4 #/% TLC#							
2	23/11/04	CL-0031	36	M	8/12/03	8	2	☒ Y ☐ N	☐ Y ☒ N	8/12/03		23/11/04	WHO stage:4 CD4 #/%: 98 TLC#	15/12/04						
3	23/11/04	CL-0032	41	M	2/11/04	1	4	☐ Y ☒ N	☐ Y ☒ N	23/11/04		23/11/05	WHO stage:3 CD4 #/%: 158 TLC#							
4	25/11/04	CL-0033	32	M	8/11/04	1	1	☐ Y ☒ N	☒ Y ☐ N				WHO stage CD4 #/% TLC#							
5	26/11/04	CL-0034	36	F	9/10/04	1	1	☒ Y ☐ N	☒ Y ☐ N	26/12/04			WHO stage CD4 #/% TLC#							
6	28/11/04	CL-0035	21	M	29/10/04	1	1	☐ Y ☒ N	☒ Y ☐ N	28/12/04			WHO stage CD4 #/% TLC#							
7	30/11/04	CL-0036	26	F	8/11/04	2	1	☒ Y ☐ N	☒ Y ☐ N	30/11/04	TB smear + Regimen I 15/11/04		WHO stage CD4 #/% TLC#							
8	30/11/04	CL-0037	25	F	5/10/02	10	5	☐ Y ☒ N	☒ Y ☐ N	30/11/04		30/11/04	WHO stage: 4 CD4 #/% TLC#	15/12/04						
9	DECEMBER 2004																			
10	1/12/04	CL-0038	39	M	9/11/04	1	4	☒ Y ☐ N	☒ Y ☐ N	2/1/05			WHO stage CD4 #/% TLC#							
11	2/12/04	CL-0039	21	M	28/11/04	1	1	☒ Y ☐ N	☐ Y ☒ N	2/12/04		2/12/04	WHO stage: 3 CD4 #/%:147 TLC#	17/12/04						
12	2/12/04	CL-0040	45	M	9/10/04	4	1	☒ Y ☐ N	☐ Y ☒ N	2/12/04		2/12/04	WHO stage:4 CD4 #/% TLC#	17/12/04						
13	5/12/04	CL-0041	28	F	12/9/04	1	1	☐ Y ☒ N	☒ Y ☐ N	5/1/05			WHO stage CD4 #/% TLC#							
14	5/12/04	CL-0042	3	M	12/9/04	1	6	☐ Y ☒ N	☐ Y ☒ N	5/12/04			WHO stage CD4 #/% TLC#							
15	5/12/04	CL-0043	65	F	2/10/04	4	1	☒ Y ☐ N	☒ Y ☐ N	5/12/04		5/12/04	WHO stage:4 CD4 #/% TLC#	20/12/04						

*Entry point: 1-VCT; 2-TB; 3-Outpatient; 4-Inpatient; 5-Paediatric; 6-PMTCT; 7-STI; 8-Private; 9-NGO; 10-Self referred; 11-IDU outreach; 12- SW outreach; 13-other - **TR if transf**
 **Risk factor for HIV: 1-Heterosexual; 2-Men who have sex with men; 3-Sex work; 4-Injecting drug use; 5- Blood transfusion; 6-Mother to child; 7-unknown
 CPT: Cotrimoxazole preventive therapy

HIV CARE- PRE ART REGISTER: Fill at first visit column 1 to 10																Fill when applicable column 11 to 16					
1	2	3	4	5	6		7	8	9	10	11	12	13	14	15	16					
DATE 1 st visit at the clinic	Registra-tion number	Name/ address	Age	Sex M/ F	Confirmed HIV+ test		Entry point code1 to 11*	risk factor code1 to 7**	Literate	Employed	CPT date start	TB treat. Class Regimen date start	DATE medical eligible for ART	Why medical eligible?	DATE ART started	End of follow-up before ART					
					Date	Place										Date lost to FU (last visit)	Date transfer . out				
1	7/12/04	CL-0044	29	F	15/9/04		1	1	☒ Y ☐ N	☒ Y ☐ N				WHO stage CD4 #/% TLC#							
2	8/12/04	CL-0045	30	M	2/12/04		1	1	☒ Y ☐ N	☐ Y ☒ N	8/12/04			WHO stage: CD4 #/%: TLC#							
3	9/12/04	CL-0046	38	M	25/11/04		1	1	☐ Y ☒ N	☐ Y ☒ N	8/12/04			WHO stage CD4 #/% TLC#							
4	12/12/04	CL-0047	19	M	1/12/04		1	1	☐ Y ☒ N	☒ Y ☐ N	12/1/05			WHO stage CD4 #/% TLC#							
5	13/12/04	CL-0048	25	F	5/6/04		3	1	☒ Y ☐ N	☒ Y ☐ N	13/12/04			WHO stage CD4 #/% TLC#							
6	14/12/04	CL-0049	24	M	20/11/04		1	1	☐ Y ☒ N	☒ Y ☐ N	14/1/05			WHO stage CD4 #/% TLC#							
7	14/12/04	CL-0050	3	F	2/12/04		5	6	☒ Y ☐ N	☒ Y ☐ N	14/12/04			WHO stage CD4 #/% TLC#							
8	14/12/04	CL-0051	36	M	8/9/02		10	4	☐ Y ☒ N	☒ Y ☐ N	14/12/04		14/12/04	WHO stage: 3 CD4 #/%:98 TLC#	28/12/04						
9	14/12/04	CL-0052	34	F	2/12/04		6	1	☐ Y ☒ N	☐ Y ☒ N	14/1/05			WHO stage CD4 #/% TLC#							
10	14/12/04	CL-0053	28	F	26/11/04		1	3	☒ Y ☐ N	☐ Y ☒ N				WHO stage CD4 #/% TLC#							
11	15/12/04	CL-0054	22	F	3/12/04		1	1	☒ Y ☐ N	☐ Y ☒ N	15/1/05			WHO stage CD4 #/% TLC#							
12	17/12/04	CL-0055	26	M	7/8/04		11	4	☒ Y ☐ N	☐ Y ☒ N	17/12/04		17/12/04	WHO stage:4 CD4 #/% TLC#							
13	17/12/04	CL-0056	47	M	5/12/04		11	4	☐ Y ☒ N	☐ Y ☒ N	17/1/05			WHO stage CD4 #/% TLC#							
14	17/12/04	CL-0057	30	M	5/12/04		11	4	☐ Y ☒ N	☐ Y ☒ N				WHO stage CD4 #/% TLC#							
15	19/12/04	CL-0058	29	F	29/11/04		1	1	☒ Y ☐ N	☒ Y ☐ N				WHO stage CD4 #/% TLC#							

*Entry point: 1-VCT; 2-TB; 3-Outpatient; 4-Inpatient; 5-Paediatric; 6-PMCTCT; 7-STI; 8-Private; 9-NGO; 10-Self referred; 11-IDU outreach; 12- SW outreach; 13-other - **TR if transf**
 **Risk factor for HIV: 1-Heterosexual; 2-Men who have sex with men; 3-Sex work; 4-Injecting drug use; 5- Blood transfusion; 6-Mother to child; 7-unknown
 CPT: Cotrimoxazole preventive therapy

HIV CARE- PRE ART REGISTER: Fill at first visit column 1 to 10																Fill when applicable column 11 to 16				
1	2	3	4	5	6		7	8	9	10	11	12	13	14	15	16				
DATE 1 st visit at the clinic	Registra-tion number	Name/ address	Age	Sex M/ F	Confirmed HIV+ test	Entry point code1 to 11*	risk factor code1 to 7**	Literate	Employed	CPT date start	TB treat. Class Regimen II date start	DATE medical eligible for ART	Why medical eligible?	DATE ART started	End of follow-up before ART	Date lost to FU (last visit)	Date transfer . out			
				Date														Place		
1	21/12/04	CL-0059	26	M	10/12/04	1	1	☐ Y ☒ N	☒ Y ☐ N	21/12/04										
2	22/12/04	CL-0060	32	F	6/12/04	2	1	☒ Y ☐ N	☒ Y ☐ N	22/12/04	TB smear + Regimen II 11/11/04	22/12/04	WHO stage:4 CD4 #/%; TLC#	7/1/05						
3	24/12/04	CL-0061	38	M	9/12/04	1	1	☐ Y ☒ N	☒ Y ☐ N	24/1/05			WHO stage CD4 #/%; TLC#							
4	28/12/04	CL-0062	24	M	15/8/04	10	1	☒ Y ☐ N	☒ Y ☐ N	28/12/04		28/12/04	WHO stage:3 CD4 #/%; TLC#	15/1/05						
5	29/12/04	CL-0063	28	M	5/12/04	1	1	☐ Y ☒ N	☒ Y ☐ N				WHO stage CD4 #/%; TLC#							
6	29/12/04	CL-0064	29	M	15/12/04	1	1	☐ Y ☒ N	☐ Y ☒ N				WHO stage CD4 #/%; TLC#							
7	JANUARY 2005																			
8	2/1/05	CL-0065	28	M	20/12/03	8	1	☐ Y ☒ N	☒ Y ☐ N	2/1/05		2/1/05	WHO stage:4 CD4 #/%; TLC#	17/1/05						
9	3/1/05	CL-0066	37	F	10/12/04	4	1	☐ Y ☒ N	☐ Y ☒ N	3/1/05		3/1/05	WHO stage 4 CD4 #/%; TLC#	18/1/05						
10	4/1/05	CL-0067	35	M	4/12/04	1	1	☒ Y ☐ N	☐ Y ☒ N	4/1/05			WHO stage CD4 #/%; TLC#							
11	6/1/05	CL-0068	21	M	25/12/04	1	1	☒ Y ☐ N	☐ Y ☒ N				WHO stage CD4 #/%; TLC#							
12	8/1/05	CL-0069	43	M	16/4/04	4	4	☒ Y ☐ N	☐ Y ☒ N	8/1/05		8/1/05	WHO stage: 4 CD4 #/%; TLC#	25/1/05						
13	10/1/05	CL-0070	31	F	2/1/05	1	1	☐ Y ☒ N	☐ Y ☒ N				WHO stage CD4 #/%; TLC#							
14	10/1/05	CL-0071	2	M	18/12/04	1	6	☐ Y ☒ N	☐ Y ☒ N	10/1/05			WHO stage CD4 #/%; TLC#							
15	11/1/05	CL-0072	21	F	2/1/04	6	1	☒ Y ☐ N	☒ Y ☐ N				WHO stage CD4 #/%; TLC#							

*Entry point: 1-VCT; 2-TB; 3-Outpatient; 4-Inpatient; 5-Paediatric; 6-PMTCT; 7-STI; 8-Private; 9-NGO; 10-Self referred; 11-IDU outreach; 12- SW outreach; 13-other - **TR if transf**
 **Risk factor for HIV: 1-Heterosexual; 2-Men who have sex with men; 3-Sex work; 4-Injecting drug use; 5- Blood transfusion; 6-Mother to child; 7-unknown
 CPT: Cotrimoxazole preventive therapy

HIV CARE- PRE ART REGISTER: Fill at first visit column 1 to 10

Fill when applicable column 11 to 16

1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16
DATE 1 st visit at the clinic	Registra-tion number	Name/ address	Age	Sex M/ F	Confirmed HIV+ test		Entry point code1 to 11*	Literate	Employed	CPT date start	TB treat. Class Regimen date start	DATE medical eligible for ART	Why medical elligible?	DATE ART started	End of follow-up before ART
					Date	Place									Date lost to FU (last visit)
1	12/1/05	CL-0073	18	M	20/12/04		1	☒ Y ☐ N	☒ Y ☐ N	12/1/05			WHO stage CD4 #/% TLC#		
2	13/1/05	CL-0074	30	M	19/10/04		1	☒ Y ☐ N	☐ Y ☒ N				WHO stage CD4 #/% TLC#		
3	15/1/05	CL-0075	25	F	28/4/04		6	☐ Y ☒ N	☐ Y ☒ N	15/1/05		15/1/05	WHO stage: 3 CD4 #/%: 79 TLC#	30/1/05	
4	18/1/05	CL-0076	36	M	7/11/04		1	☐ Y ☒ N	☒ Y ☐ N				WHO stage CD4 #/% TLC#		
5	18/1/05	CL-0077	34	F	20/12/04		1	☒ Y ☐ N	☒ Y ☐ N				WHO stage CD4 #/% TLC#		
6	19/1/05	CL-0078	24	F	7/1/05		4	☐ Y ☒ N	☐ Y ☒ N	19/1/05		19/1/05	WHO stage 4 CD4 #/% TLC#		
7	20/1/05	CL-0079	3	F	10/1/05		1	☒ Y ☐ N	☒ Y ☐ N	20/1/05			WHO stage CD4 #/% TLC#		
8	21/1/05	WY0029 CL-0080	22	M	7/3/04		TR	☐ Y ☒ N	☒ Y ☐ N			1/10/04	WHO stage 4 CD4 #/% 79 TLC#	20/10/04	
9	23/1/05	CL-0081	28	M	10/1/05		2	☐ Y ☒ N	☐ Y ☒ N	5/1/05	TB smear + regimen I 5/1/05	23/1/05	WHO stage: 4 CD4 #/% TLC#		
10	27/1/05	CL-0082	33	F	2/3/04		3	☐ Y ☒ N	☐ Y ☒ N	27/1/05		27/1/05	WHO stage 4 CD4 #/% TLC#		
11	28/1/05	CL-0083	24	M	21/8/04		8	☒ Y ☐ N	☐ Y ☒ N	28/1/05		28/1/05	WHO stage: 3 CD4 #/%: 160 TLC#		
12	28/1/05	CL-0084	38	M	10/1/05		1	☒ Y ☐ N	☐ Y ☒ N				WHO stage CD4 #/% TLC#		
13	29/1/05	CL-0085	36	M	11/1/05		4	☐ Y ☒ N	☒ Y ☐ N	29/1/05		29/1/05	WHO stage: 4 CD4 #/% TLC#		
14	30/1/05	CL-0086	29	F	15/12/04		1	☒ Y ☐ N	☐ Y ☒ N				WHO stage CD4 #/% TLC#		
15	30/1/05	CL-0087	42	M	3/1/05		1	☒ Y ☐ N	☒ Y ☐ N	30/1/05			WHO stage CD4 #/% TLC#		

 *Entry point: 1-VCT; 2-TB; 3-Outpatient; 4-Inpatient; 5-Paediatric; 6-PMTCT; 7-STI; 8-Private; 9-NGO; 10-Self referred; 11-IDU outreach; 12- SW outreach; 13-other - **TR if transf**

**Risk factor for HIV: 1-Heterosexual; 2-Men who have sex with men; 3-Sex work; 4-Injecting drug use; 5- Blood transfusion; 6-Mother to child; 7-unknown

CPT: Cotrimoxazole preventive therapy

**ART Register
Clinic CL**

ART REGISTER

Month: October

Year: 2004

DATE of start of ART	Registra- tion number	Name	Age	Sex M/ F	Received ARV before starting	WHO stage at start	Performan- ce scale A-normal activity B-bedridden<50% C-bedridden>50%	Weight (kg) & height (cm)	CD4 count (% for children)	TB Rx. Disease class Regimen Date Rx start	ART regimen started	Treatment substitute within 1st line drugs			Treatment switched for 2nd line			End of follow-up on ART			Monthly visits: • 1st row, write patient outcome: on treatment (OT) if patient-					
												Date	Rea- son *	New Regimen	Date	Rea- son **	New Regimen	Date of death	Date lost to FU* (last visit)	Date transfer Out on ART	we.	mo.	1	2	mo.	mo.
15/10/04	CL-0002		36	M	☐ Y ☒ N	4	At start At 6 mo. 62/178 At 12 mo. At 24 mo.	At start At 6 mo. 59 At 12 mo. At 24 mo.	At start At 6 mo. 59 At 12 mo. At 24 mo.	TB SMEAR + REGIMEN I 20/11/04	D4T40 /3TC /NVP	30/12/ 04	4	D4T40/3TC + EFV						OT	ST	RS	OT			
26/10/04	CL-0006		32	F	☐ Y ☒ N	4	At start At 6 mo. 45/165 At 12 mo. At 24 mo.	At start At 6 mo. Not Done At 12 mo. At 24 mo.	At start At 6 mo. Not Done At 12 mo. At 24 mo.		D4T30 /3TC /NVP									OT	MIS	MIS				
28/10/04	CL-0003		24	F	☒ Y ☐ N	3	At start At 6 mo. 62/173 At 12 mo. At 24 mo.	At start At 6 mo. 168 At 12 mo. At 24 mo.	At start At 6 mo. 168 At 12 mo. At 24 mo.	TB SMEAR + REGIMEN I 15/7/04	D4T40 /3TC /EFV									OT	OT	OT	OT			
31/10/04	CL-0011		29	M	☐ Y ☒ N	4	At start At 6 mo. 53/175 At 12 mo. At 24 mo.	At start At 6 mo. 26 At 12 mo. At 24 mo.	At start At 6 mo. 26 At 12 mo. At 24 mo.		D4T30 /3TC /NVP	30/12/ 04	1	AZT/3TC /NVP							OT	OT	OT	OT		
20/10/04	WY-0029 CL-0080		22	M	☐ Y ☒ N	4	At start At 6 mo. 62/175 At 12 mo. At 24 mo.	At start At 6 mo. 79 At 12 mo. At 24 mo.	At start At 6 mo. 79 At 12 mo. At 24 mo.		D4T40 /3TC /NVP									TR IN	21/1/05	OT				
					☐ Y ☐ N		At start At 6 mo. At 12 mo. At 24 mo.	At start At 6 mo. At 12 mo. At 24 mo.	At start At 6 mo. At 12 mo. At 24 mo.																	
					☐ Y ☐ N		At start At 6 mo. At 12 mo. At 24 mo.	At start At 6 mo. At 12 mo. At 24 mo.	At start At 6 mo. At 12 mo. At 24 mo.																	
					☐ Y ☐ N		At start At 6 mo. At 12 mo. At 24 mo.	At start At 6 mo. At 12 mo. At 24 mo.	At start At 6 mo. At 12 mo. At 24 mo.																	
					☐ Y ☐ N		At start At 6 mo. At 12 mo. At 24 mo.	At start At 6 mo. At 12 mo. At 24 mo.	At start At 6 mo. At 12 mo. At 24 mo.																	
					☐ Y ☐ N		At start At 6 mo. At 12 mo. At 24 mo.	At start At 6 mo. At 12 mo. At 24 mo.	At start At 6 mo. At 12 mo. At 24 mo.																	

Reasons SUBSTITUTE/SWITCH: 1 toxicity side effects, 2 pregnancy, 3 risk of pregnancy, 4 newly diagnosed TB, 5 new drug available, 6 drug out of stock, 7 other reason

Reasons for SWITCH only: 8 clinical treatment failure, 9 immunological failure, 10 virologic failure

Reasons STOP: 1 toxicity side effects, 2 pregnancy, 3 treatment failure, 4 poor adherence, 5 illness hospitalisation, 6 drug out of stock, 7 patient lack of finance, 8 other patient decision, 9 other planned treatment interruption, 10 other

* patient missing for more than 3 mo.

ART REGISTER

Month: November

Year: 2004

DATE of start of ART	Registra- tion number	Name	Age	Sex M/ F	Received ARV before starting	WHO stage at start	Performance scale A-normal activity B-bedridden<50% C-bedridden>50%	Weight (kg) & height (cm)	CD4 count (% for children)	TB Rx. during ART Disease class Regimen Date Rx start	ART regimen started	Treatment substitute within 1st line drugs			Treatment switched for 2nd line		End of follow-up on ART			Monthly visits: • 1st row, write patient outcome on treatment (OT) if patient-				
												Date	Rea-son *	New Regimen	Date	Rea-son **	New Regimen	Date of death	Date lost to FU* (last visit)	Date transfer Out on ART	we.	mo.	1	2
1/11/04	CL-0010		32	F	☐ Y ☒ N	4	Ai start B Ai 6 mo. Ai 12 mo. Ai 24 mo.	Ai start 63/170 Ai 6 mo. Ai 12 mo. Ai 24 mo.	Ai start 148 Ai 6 mo. Ai 12 mo. Ai 24 mo.		D4T40/ 3TC/ NVP								OT	OT				
7/11/04	CL-0014		36	M	☐ Y ☒ N	4	Ai start C Ai 6 mo. Ai 12 mo. Ai 24 mo.	Ai start 46/162 Ai 6 mo. Ai 12 mo. Ai 24 mo.	Ai start ND Ai 6 mo. Ai 12 mo. Ai 24 mo.		D4T30/ 3TC/ NVP	20/11/ 04	1	D4T30/3TC + EFV				27/1/ 05			OT	OT	D	
15/11/04	CL-0016		26	M	☐ Y ☒ N	3	Ai start A Ai 6 mo. Ai 12 mo. Ai 24 mo.	Ai start 69/175 Ai 6 mo. Ai 12 mo. Ai 24 mo.	Ai start 91 Ai 6 mo. Ai 12 mo. Ai 24 mo.		D4T40/ 3TC/ NVP									OT	MIS	OT		
15/11/04	CL-0017		36	F	☐ Y ☒ N	4	Ai start C Ai 6 mo. Ai 12 mo. Ai 24 mo.	Ai start 51/168 Ai 6 mo. Ai 12 mo. Ai 24 mo.	Ai start 14 Ai 6 mo. Ai 12 mo. Ai 24 mo.		D4T30/ 3TC/ NVP						20/12/ 04			MIS	D			
18/11/04	CL-0022		51	M	☐ Y ☒ N	4	Ai start C Ai 6 mo. Ai 12 mo. Ai 24 mo.	Ai start 61/176 Ai 6 mo. Ai 12 mo. Ai 24 mo.	Ai start 38 Ai 6 mo. Ai 12 mo. Ai 24 mo.	EPTB REGIMEN I 23/12/04	D4T40/3 TC /NVP									OT	ST	ST		
18/11/04	CL-0026		37	M	☐ Y ☒ N	4	Ai start B Ai 6 mo. Ai 12 mo. Ai 24 mo.	Ai start 51/176 Ai 6 mo. Ai 12 mo. Ai 24 mo.	Ai start ND Ai 6 mo. Ai 12 mo. Ai 24 mo.		D4T30 /3TC /NVP									OT	OT	OT		
26/11/04	CL-0025		32	F	☐ Y ☒ N	4	Ai start C Ai 6 mo. Ai 12 mo. Ai 24 mo.	Ai start 58/172 Ai 6 mo. Ai 12 mo. Ai 24 mo.	Ai start 96 Ai 6 mo. Ai 12 mo. Ai 24 mo.	TB SMEAR+ REGIMEN II 12/4/04	D4T30/3 TC + EFV									OT	OT	OT		
					☐ Y ☐ N		Ai start Ai 6 mo. Ai 12 mo. Ai 24 mo.	Ai start Ai 6 mo. Ai 12 mo. Ai 24 mo.	Ai start Ai 6 mo. Ai 12 mo. Ai 24 mo.															
					☐ Y ☐ N		Ai start Ai 6 mo. Ai 12 mo. Ai 24 mo.	Ai start Ai 6 mo. Ai 12 mo. Ai 24 mo.	Ai start Ai 6 mo. Ai 12 mo. Ai 24 mo.															
					☐ Y ☐ N		Ai start Ai 6 mo. Ai 12 mo. Ai 24 mo.	Ai start Ai 6 mo. Ai 12 mo. Ai 24 mo.	Ai start Ai 6 mo. Ai 12 mo. Ai 24 mo.															

* patient missing for more than 3 mo.

Reasons SUBSTITUTE/SWITCH: 1 toxicity side effects, 2 pregnancy, 3 risk of pregnancy, 4 newly diagnosed TB, 5 new drug available, 6 drug out of stock, 7 other reason

Reasons for SWITCH only: 8 clinical treatment failure, 9 immunological failure, 10 virologic failure

Reasons STOP: 1 toxicity side effects, 2 pregnancy, 3 treatment failure, 4 poor adherence, 5 illness hospitalisation, 6 drug out of stock, 7 patient lack of finance, 8 other patient decision, 9 other planned treatment interruption, 10 other

ART REGISTER

Month: December

Year: 2004

DATE of start of ART	Registra- tion number	Name	Age	Sex M/ F	Received ARV before starting	WHO stage at start	Performance scale A-normal activity B-bedridden<50% C-bedridden>50%	Weight (kg) & height (cm)	CD4 count (% for children)	TB Rx. Disease class Regimen Date Rx start	ART regimen started	Treatment substitute within 1st line drugs			Treatment switched for 2nd line		End of follow-up on ART			Monthly visits: • 1s row, write patient outcome on treatment (OT) if patient-				
												Date	Rea-son *	New Regimen	Date	Rea-son **	New Regimen	Date of death	Date lost to FU* (last visit)	Date transfer Out on ART	we. 2	mo. 1	mo. 2	mo. 3
6/12/04	CL-0018		28	M	☐ Y ☒ N	4	At start At 6 mo. At 12 mo. At 24 mo.	At start 57/172 At 12 mo. At 24 mo.	At start ND At 12 mo. At 24 mo.		D4T30/ 3TC/ NVP									OT	OT			
15/12/04	CL-0005		18	M	☐ Y ☒ N	3	At start At 6 mo. At 12 mo. At 24 mo.	At start 70/175 At 12 mo. At 24 mo.	At start 140 At 12 mo. At 24 mo.		D4T40/ 3TC/ NVP									OT	OT			
15/12/04	CL-0031		36	M	☒ Y ☐ N	4	At start At 6 mo. At 12 mo. At 24 mo.	At start 65/175 At 12 mo. At 24 mo.	At start 98 At 12 mo. At 24 mo.		D4T40/ 3TC/ NVP									OT	OT			
15/12/04	CL-0037		25	F	☐ Y ☒ N	4	At start At 6 mo. At 12 mo. At 24 mo.	At start 58/167 At 12 mo. At 24 mo.	At start ND At 12 mo. At 24 mo.		D4T30/ 3TC/ NVP									OT	OT			
17/12/04	CL-0039		21	M	☐ Y ☒ N	3	At start At 6 mo. At 12 mo. At 24 mo.	At start 65/170 At 12 mo. At 24 mo.	At start 147 At 12 mo. At 24 mo.		D4T40/ 3TC/ NVP									OT	OT			
17/12/04	CL-0040		45	M	☐ Y ☒ N	4	At start At 6 mo. At 12 mo. At 24 mo.	At start 52/168 At 12 mo. At 24 mo.	At start ND At 12 mo. At 24 mo.		D4T30/ 3TC/ NVP									OT	OT			
20/12/04	CL-0043		65	F	☐ Y ☒ N	4	At start At 6 mo. At 12 mo. At 24 mo.	At start 41/165 At 12 mo. At 24 mo.	At start ND At 12 mo. At 24 mo.		D4T30/ 3TC/ NVP									OT	OT			
20/12/04	CL-0021		3	F	☐ Y ☒ N	3	At start At 6 mo. At 12 mo. At 24 mo.	At start 10/80 At 12 mo. At 24 mo.	At start 8% At 12 mo. At 24 mo.		D4T/ 3TC/ NVP junior									OT	OT			
22/12/04	CL-0024		29	M	☐ Y ☒ N	3	At start At 6 mo. At 12 mo. At 24 mo.	At start 72/175 At 12 mo. At 24 mo.	At start 180 At 12 mo. At 24 mo.		D4T40/ 3TC/ NVP									OT				
28/12/04	CL-0051		36	M	☐ Y ☒ N	3	At start At 6 mo. At 12 mo. At 24 mo.	At start 66/176 At 12 mo. At 24 mo.	At start 98 At 12 mo. At 24 mo.		D4T40/ 3TC/ NVP									OT	OT			

Reasons SUBSTITUTE/SWITCH:

Reasons for SWITCH only:

Reasons STOP:

1 toxicity side effects, 2 pregnancy, 3 risk of pregnancy, 4 newly diagnosed TB, 5 new drug available, 6 drug out of stock, 7 other reason

8 clinical treatment failure, 9 immunological failure, 10 virologic failure

1 toxicity side effects, 2 pregnancy, 3 treatment failure, 4 poor adherence, 5 illness hospitalisation, 6 drug out of stock, 7 patient lack of finance, 8 other patient decision, 9 other planned treatment interruption, 10 other

* patient missing for more than 3 mo.

ART REGISTER

Year:2005

Month: January

DATE of start of ART	Registra- tion number	Name	Age	Sex M/ F	Received ARV before starting	WHO stage at start	Performance scale A-normal activity B-bedridden<50% C-bedridden>50%	Weight (kg) & height (cm)	CD4 count (% for children)	TB Rx. during ART Disease class Regimen Date Rx start	ART regimen started	Treatment substitute within 1st line drugs			Treatment switched for 2nd line		End of follow-up on ART			Monthly visits: ● 1st row, write patient outcome: on treatment (OT) if patient-						
												Date	Rea- son *	New Regimen	Date	Rea- son **	New Regimen	Date of death	Date lost to FU* (last visit)	Date transfer Out on ART	we.	mo.	1	2	3	4
2/1/05	CL-0007		45	F	☐ Y ☒ N	3	At start At 6 mo. 62/169 At 12 mo. At 24 mo.	At start At 6 mo. ND At 12 mo. At 24 mo.	At start At 6 mo. ND At 12 mo. At 24 mo.		D4T40/ 3TC/ NVP									OT						
7/1/05	CL-0012		22	M	☐ Y ☒ N	4	At start At 6 mo. 58/170 At 12 mo. At 24 mo.	At start At 6 mo. 79 At 12 mo. At 24 mo.	At start At 6 mo. 79 At 12 mo. At 24 mo.		D4T30/ 3TC/ NVP										OT					
7/1/05	CL-0060		32	F	☐ Y ☒ N	4	At start At 6 mo. 57/168 At 12 mo. At 24 mo.	At start At 6 mo. ND At 12 mo. At 24 mo.	At start At 6 mo. ND At 12 mo. At 24 mo.	PTB SMEAR+ REGIMEN II 11/11/04	D4T30/ 3TC/ NVP										OT					
15/1/05	CL-0062		24	M	☐ Y ☒ N	3	At start At 6 mo. 69/175 At 12 mo. At 24 mo.	At start At 6 mo. 121 At 12 mo. At 24 mo.	At start At 6 mo. 121 At 12 mo. At 24 mo.		D4T40/ 3TC/ NVP										A					
17/1/05	CL-0066		28	M	☐ Y ☒ N	4	At start At 6 mo. 63/175 At 12 mo. At 24 mo.	At start At 6 mo. 18 At 12 mo. At 24 mo.	At start At 6 mo. 18 At 12 mo. At 24 mo.		D4T40/3 TC /NVP															
18/1/05	CL-0067		37	F	☐ Y ☒ N	4	At start At 6 mo. 55/170 At 12 mo. At 24 mo.	At start At 6 mo. 65 At 12 mo. At 24 mo.	At start At 6 mo. 65 At 12 mo. At 24 mo.		D4T30 /3TC /NVP															
25/1/05	CL-0070		43	M	☐ Y ☒ N	4	At start At 6 mo. 56/175 At 12 mo. At 24 mo.	At start At 6 mo. ND At 12 mo. At 24 mo.	At start At 6 mo. ND At 12 mo. At 24 mo.		D4T30/3 TC /NVP															
30/1/05	CL-0076		25	F	☐ Y ☒ N	3	At start At 6 mo. 63/172 At 12 mo. At 24 mo.	At start At 6 mo. 179 At 12 mo. At 24 mo.	At start At 6 mo. 179 At 12 mo. At 24 mo.		D4T40/3 TC /NVP															
					☐ Y ☐ N		At start At 6 mo. At 12 mo. At 24 mo.	At start At 6 mo. At 12 mo. At 24 mo.	At start At 6 mo. At 12 mo. At 24 mo.																	
					☐ Y ☐ N		At start At 6 mo. At 12 mo. At 24 mo.	At start At 6 mo. At 12 mo. At 24 mo.	At start At 6 mo. At 12 mo. At 24 mo.																	

* patient missing for more than 3 mo.

Reasons SUBSTITUTE/SWITCH: 1 toxicity side effects, 2 pregnancy, 3 risk of pregnancy, 4 newly diagnosed TB, 5 new drug available, 6 drug out of stock, 7 other reason

Reasons for SWITCH only: 8 clinical treatment failure, 9 immunological failure, 10 virologic failure

Reasons STOP: 1 toxicity side effects, 2 pregnancy, 3 treatment failure, 4 poor adherence, 5 illness hospitalisation, 6 drug out of stock, 7 patient lack of finance, 8 other patient decision, 9 other planned treatment interruption, 10 other

Report from December 2004

- CL

A- MEDICAL CARE

2. MEDICAL CARE				
6. Enrollment in HIV care (PLWHA seeking care at the treatment center)	adult male	adult female	child.<14 yo	total
6.1 Cumulative no. of patients ever enrolled in HIV care at beginning of this month	21	13	2	37
6.2 New patients enrolled in HIV care during this month	16	9	2	27
6.3 Cumulative no. of patients ever enrolled in HIV care at the end of this month	37	23	4	64
7. Medical eligibility for ART*	adult male	adult female	child.<14 yo	total
7.1 No. of patients medically eligible for ART but have not been started on ART at the end of this month	3	2	0	5
8. Enrollment on ART	adult male	adult female	child.<14 yo	total
8.1 Cumulative no. of patients ever started on ART at the beginning of this month	6	5	0	11
8.2 New patients started on ART during this month	7	2	1	10
8.3 No. of patients on ART transferred in this month	0	0	0	0
8.4 Cumulative no. of patients ever started on ART at the end of this month	13	7	1	21
9. outcomes on ART	adult male	adult female	child.<14 yo	total
9.1 Cumulative no. of death reported at the end of this month				1
9.2 Cumulative no. of patients transferred out under ARV at the end of this month				0
9.3 No. of patients missing/lost to follow-up at the end of this month				2
9.4 No. of patients stopping ART at the end of this month				1
9.5 No. of patients on ART at the end of this month				17
9.5.1 Among them, no. on original 1st line regimen				14
9.5.2 No. on substituted 1st line regimen				3
9.5.3 No. switched on 2nd line regimen				0

* refers to the medical eligibility on clinical and/or laboratory criteriae, whether or not the patient is ready for ART

10. TREATMENT ADHERENCE

10. TREATMENT ADHERENCE		Total
10.1. No. of patients assessed for adherence during this month		11
10.2. Of those assessed for adherence, level of adherence in the last month		
10.2.1. < 3 doses missed in a period of 30 days	> 95%	10
10.2.2. =3 to 12 doses missed in a period of 30 days	80-95%	
10.2.3. >12 doses missed in a period of 30 days	<80%	1

B- PHARMACY

11. REGIMEN AT THE END OF THE MONTH

Regimen	No. of patients on ART
D4T30/3TC/NEV	5
D4T40/3TC/NEV	6
ZDV/3TC/NEV	1
ZDV/3TC/EFV	0
D4T30/3TC/EFV	2
D4T40/3TC/EFV	2
+ D4T/3TC/NVP junior 12 mg	1
Total= cumulative no. of patients on ART at the end of this month (=9.6)	17

Question: Complete the report for the month of January 2005

Answer sheet exercise 3

1. Name of the Treatment Unit _____
2. Name of the District _____
3. Name of the State/province _____
4. Name of the Treatment Unit in charge _____
5. Report for the period month year

A- MEDICAL CARE

6. Enrollment in HIV care (PLWHA seeking care at the treatment center)	adult male	adult female	child.<14 yo	total
6.1 Cumulative no. of patients ever enrolled in HIV care at beginning of this month				
6.2 New patients enrolled in HIV care during this month				
6.3 Cumulative no. of patients ever enrolled in HIV care at the end of this month				
7. Medical eligibility for ART*	adult male	adult female	child.<14 yo	total
7.1 No. of patients medically eligible for ART but have not been started on ART at the end of this month				
8. Enrollment on ART	adult male	adult female	child.<14 yo	total
8.1 Cumulative no. of patients ever started on ART at the beginning of this month				
8.2 New patients started on ART during this month				
8.3 No. of patients on ART transferred in this month				
8.4 Cumulative no. of patients ever started on ART at the end of this month				
9. outcomes on ART	adult male	adult female	child.<14 yo	total
9.1 Cumulative no. of death reported at the end of this month				
9.2 Cumulative no. of patients transferred out under ARV at the end of this month				
9.3 No. of patients missing/lost to follow-up at the end of this month				
9.4 No. of patients stopping ART at the end of this month				
9.5 No. of patients on ART at the end of this month				
9.5.1 Among them, no. on original 1st line regimen				
9.5.2 No. on substituted 1st line regimen				
9.5.3 No. switched on 2nd line regimen				

* refers to the medical eligibility on clinical and/or laboratory criteriae, whether or not the patient is ready for ART

10. TREATMENT ADHERENCE		Total
10.1. No. of patients assessed for adherence during this month		
10.2. Of those assessed for adherence, level of adherence in the last month		
10.2.1. < 3 doses missed in a period of 30 days	> 95%	
10.2.2. =3 to 12 doses missed in a period of 30 days	80-95%	
10.2.3. >12 doses missed in a period of 30 days	<80%	

B- PHARMACY

11. REGIMEN AT THE END OF THE MONTH	
Regimen	No. of patients on ART
D4T30/3TC/NEV	
D4T40/3TC/NEV	
ZDV/3TC/NEV	
ZDV/3TC/EFV	
D4T30/3TC/EFV	
D4T40/3TC/EFV	
+ D4T/3TC/NVP junior 12 mg	
Total= cumulative no. of patients on ART at the end of this month (=9.6)	

Exercise 4- Cohort report

Refer to Participant Manual - Module 6

This exercise will help you in understanding how to complete a cohort report at 6 months and at 12 months. Using the ART register, you will have to compile the information available in the cohort report.

This exercise contains 2 different questions.

- ◆ Question 1: refer to the ART Register #1. All patients were registered during the month of December 2004. Report the 6-month outcomes of these patients in the Cohort Report form.
- ◆ Question 2: refer to the ART Register #2. All patients were registered in the month of June 2004. Report the 6-month and 12-month outcomes of these patients in the Cohort Report form.

Question 1: refer to the ART Register #1 (1 page). All patients were registered during the month of December 2004. Report the 6-month outcomes of these patients in the Cohort Report form.

DATE of start of ART	Registra- tion number	WHO stage at start of Rx	performance scale A-normal activity B-bedridden<50% C-bedridden>50%	CD4 count (% for children)		ART regimen started	Treatment substituted within 1st line drugs		Treatment switched to 2nd line drugs			End of follow-up on ART			Monthly visits: * 1st row, write patient outcome; on treatment (OT) if patient picked up ART drugs; stopped (ST) if ART was stopped by the doctor; missing (MS) if the patient was not seen for 2 months; lost to follow-up (LFU) if the patient was not seen for 23 months; restart (RS) if ART was restarted after an interruption; transferred out (TR); died (D); (NA) if the patient was not scheduled to visit this month * 2nd row: write adherence for the patients on treatment (A=95%, B=90-95%, C=80%)																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																	
				At start	At 6 mo.		Date	Rea- son*	New Regimen	Date	Rea- son*	New Regimen	Date of death	Date lost to FU (last visit)	Date transf- ered out	Week 2	m1	m2	m3	m4	m5	m6	m7																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																									
2/12/04		III	At start B At 12 mo. At 24 mo.	At 6 mo. A At 12 mo. At 24 mo.	At start 170 At 12 mo. At 24 mo.	At 6 mo. 190 At 24 mo.	d4T+3TC +NVP																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																									

1

2

3

4

5

6

7

8

9

10

Answer sheet exercise 4 question 2

For cohort starting ART by month/year: at baseline then results at 6 months on ART, 12 months on ART, 24 months on ART

[illegible]

Exercise 5- Cohort interpretation

Refer to Participant Manual – Module 6

This exercise will help you in understanding how to analyse the cohort report at 6 and at 12 months. Using a completed cohort report, you will have to compile all the results, present the results in graphs and prepare a short presentation.

This exercise contains 2 different questions. The first question focuses on the analysis of the trends of results at 6 months for quarterly cohorts (all patients who have started in a 3 months period). The second question compares the results at 6 and 12 months for the total cohort of patients who have started.

Question 1: Cohort report from clinic CLA in District A

This cohort report (3 pages) contains results at 6 months per monthly cohort, for patients starting ART from April 2004 to March 2005, first year of the ART programme in clinic CLA.

Analyse the continuation of ART at 6 months (% patients alive and on treatment) for the total cohort (for all patients who started from April 04 to March 05) and quarterly cohorts (for patients started in a given quarter).

- ◆ Complete the table below to compile the results of the different quarterly cohorts.

Table: Evolution of the proportion of patients on ART at 6 months according to the quarter they started. Clinic CLA, District A. Period from April 2004 to March 2005.

Quarterly cohort	2Q-04	3Q-04	4Q-04	1Q-05	TOTAL
Number started on ART in this clinic	120	..	..	..	..
Number transferred In	0	..	..	..	..
Number transferred Out	0	..	..	..	..
Total Number in Cohort started on ART	120	..	..	..	..
Number alive and on treatment at 6 month	84	237	123	202	646
Number on 1st line regimen	84	237	123	202	646
Number on alternate 1st line regiment	0	0	0	0	0
Number on 2nd line regimen (switched)	0	0	0	0	0
Died	30	31	6	7	74
Stopped on medical advice	0	0	0	0	0
Lost to Follow-up	6	12	17	9	44
Percent of cohort alive and on ART at 6 months	..	..	..	..	..

- ◆ Prepare a graph of the proportion of patients on ART per quarter.
- ◆ Interpret the change in proportion of patients on ART per quarter with regard to fatality and defaulter rates.
- ◆ Comment on the continuation of 1st line regimen.
- ◆ Prepare a query list for requesting any additional information.

Treatment unit: CLA

District: A

One cohort is defined as all patients who started ART in the same month/year April-2004 to April-2005.

Cohort starting ART in month/year: baseline result then results at 6 months on ART, 12 months on ART, 24 months on ART													
	Cohort Apr04	6 mo	12 mo Apr05	24 mo- mo- Apr06	Cohort May 04	6 mo	12 mo- May05	24 mo- May06	Cohort Jun04	6 mo	12 mo Jun05	24 mo Jun06	
A	17	17			67	67			36	36			
B	0	0											
C	0	0											
D	17	17			67	67			36	36			
E	11					46				27			
F	11					46				27			
G													
H													
I		6				18				6			
J													
K	0					3				3			
L	-	65%	-	-	-	69%	-		-	75%	-		
M													
N													
O													
P													
Q													
R		100%	100%			100%	100%			100%	100%		
		11 /11	11 /11			46/46	46/46			27/27	27/27		

atment unit: CLA

District: A

ort 04	6 mo	12 mo Dec05	24 mo- Dec06	Cohort Jan05	6 mo	12 mo Jan06	24 mo- Jan07	Cohort Feb05	6 mo	12 mo Feb06	24 mo- Feb07	Cohort Mar05	6 mo	12 mo Mar06	24 mo- Mar07	Cohort Apr05	6 mo
5	66			47	47			75	75			100	100			71	
								2									
					1												
5	66			47	46			75	73			100	99			71	
	58			39					68				95				
	58			39					68				95				
	3			6				1					0				
	5				1			4					4				
	88%	-	-	-	85%	-	-	-	93%	-	-	-	96%	-	-	-	-
	100%				100%				100%				100%				
	58/58			39/39					68/68				95/95				

Question 2: Cohort report from clinic ZY in District B

This report contains results at 6 and 12 months per monthly cohort, for patients starting ART from April 2004 to April 2005, in the first year of the ART programme in clinic ZY.

Analyse the outcomes at 6 and 12 months for the total cohort (all patients who started from April 2004 to April 2005).

- ◆ Complete the table below to compile the results of the different monthly cohorts.

Table: Outcomes at 6 months and 12 months for patients starting ART in clinic ZY, District B, from April 04 to April 05

	Baseline	%	6 months	%	12 months	%
Number started on ART in this clinic	1125		...		...	
Number transferred In	0		...		...	
Number transferred Out	0		...		...	
Total Number in Cohort started on ART (A)	1125		...		...	
Number alive and on treatment (B)			949	...	...	...
Number on 1st line regimen			888	...	313	...
Number on alternate 1st line regimen			61	...	43	...
Number on 2nd line regimen (switched)			0	...	0	...
Died			86	...	...	...
Stopped on medical advice			65	...	38	...
Lost to Follow-up			25	...	9	...
Functional status among patients alive on ART						
Working	715	63.4	860	...	325	...
Ambulatory	260	23.1	61	...	18	...
Bedridden	152	13.5	27	...	13	...

- ◆ Prepare a graph depicting the proportion of patients alive and on ART, deceased, stopped and lost to follow-up.
- ◆ Analyse the proportion of substitution and switch in regimen at 6 and 12 months.
- ◆ Analyse the functional status at 6 and 12 months and prepare a graph.
- ◆ Interpret the outcomes, changes in regimen and functional status of the cohort.
- ◆ Prepare a query list for requesting any additional information.

Treatment unit: ZY

District: B

Cohort starting ART in month/year: baseline result then results at 6 months on ART, 12 months on ART, 24 months on ART												
	Cohort Apr04	6 mo	12 mo Apr05	24 mo- Apr06	Cohort May 04	6 mo	12 mo- May05	24 mo- May06	Cohort Jun04	6 mo	12 mo Jun05	24 mo- Jun06
A	150	150	150	-	87	87	87		73	73	73	
B	-	-	-	-								
C	-	-	-	-								
D	150	150	150	-	87	87	87		73	73	73	
E		130	126			61	61			62	60	
F		125	114			57	50			59	54	
G						4	11			3	6	
H												
I		9	10			14	14			2	2	
J		11	12			12	12			7	7	
K		0	2			0	0			2	4	
L	-	87%	84%	-	-	70%	70%		-	85%	82%	
M	97	357	415		94	354	389		98	340	395	
N												
O	88 /150 59%	120/130 92%	118/126 93%		50 / 87 57%	55 /61 90%	58 / 61 95%		40 / 73 55%	56 / 62 90%	56 / 60 93%	
P	48 /150 32%	8 / 130 6%	4 /126 3%		25/ 87 29%	4 / 61 7%	2 / 61 3%		20/ 73 27%	4 / 62 6%	2 / 60 3%	
R	14 /150 9%	2 / 130 2%	4 / 126 3%		12/ 87 14%	2 / 61 3%	1 / 61 2%		13/ 73 18%	2 / 62 3%	2 / 60 3%	
		130/130 100%	124/126 98%			60 /61 98%	59 / 61 96%			60 / 62 97%	57 / 60 95%	
	Number of people in cohort who consistently every month (6/6 and 12/12) picked up their ARVs											

Treatment unit: ZY				District: B								Treatment unit: ZY							
Cohort Jul04	6 mo	12 mo Jul05	24 mo-Jul06	Cohort Aug04	6 mo	12 mo Aug05	24 mo-Aug06	Cohort Sep04	6 mo	12 mo-Sep05	24 mo-mo-Sep06	Cohort Oct04	6 mo	12 mo Oct05	24 mo-mo-Oct06	Cohort Nov04	6 mo	12 mo Nov05	Cohort Dec04
38	38	38		45	45	45		45	45	45		62	62			56	56		90
38	38	38		45	45	45		45	45	45		62	62			56	56		90
	31	30			40	39			40	40			52				49		
	28	25			37	34			37	36			48				42		
	3	5			3	5			3	4			4				7		
	3	3			2	3			3	3			4				5		
	3	3			3	3			1	1			4				0		
	1	2			0	0			1	1			2				2		
-	82%	79%	-	-	89%	87%	-	-	89%	89%	-	-	84%		-	-	88%		8
94	302	358		102	376	360		86	299	298		91	346			107	334		94
19 / 38 50%	26 / 31 83%	27 / 30 90%		22 / 45 49%	30 / 40 75%	33 / 39 84%		23 / 45 51%	31 / 40 78%	33 / 40 93%		40 / 62 65%	48 / 52 92%			30 / 56 54%	42 / 49 86%		51 / 90 57%
8 / 38 21%	4 / 31 13%	1 / 30 3%		12 / 45 27%	6 / 40 15%	4 / 39 10%		11 / 45 24%	7 / 40 18%	5 / 40 13%		12 / 62 19%	2 / 52 4%			20 / 56 36%	4 / 49 8%		24 / 90 27%
10 / 38 26%	1 / 31 4%	2 / 30 6%		11 / 45 24%	4 / 40 10%	2 / 39 5%		11 / 45 24%	2 / 40 6%	2 / 40 6%		10 / 62 16%	2 / 52 4%			6 / 56 11%	3 / 49 6%		8 / 90 9%
	30 / 31 97%	28 / 30 93%			38 / 40 98%	37 / 39 95%			38 / 40 95%	37 / 40 93%			50 / 52 96%				47 / 49 95%		

ient unit: ZY

District: B

6 mo	12 mo Dec05	24 mo- Dec06	Cohort Jan05	6 mo	12 mo Jan06	24 mo- Jan07	Cohort Feb05	6 mo	12 mo Feb06	24 mo- Feb07	Cohort Mar05	6 mo	12 mo Mar06	24 mo- Mar07	Cohort Apr05	6 mo
90			106	106			131	131			123	123			119	119
90			106	106			131	131			123	123			119	119
72				90				109				107				106
67				84				104				102				98
5				6				5				5				8
8				9				9				9				9
5				4				4				7				4
5				3				9				0				0
80%		-	-	85%		-	-	83%		-	-	87%		-	-	89%
320			90	323			96	326			98	298			98	318
65 / 72 90%			83/106 78%	87 / 90 97%			88/131 67%	100/109 92%			93/123 76%	100/107 93%			88/119 74%	100/106 94%
5 / 72 7%			10/106 9%	1 / 90 1%			24/131 18%	7 / 109 6%			20/123 16%	5 / 107 5%			26/119 22%	4 / 106 4%
2 / 72 3%			13/106 12%	2 / 90 2%			19/131 15%	2 / 109 2%			10/123 8%	2 / 107 2%			15/119 13%	1 / 106 1%
69 / 72 96%				87 / 90 97%				105/109 96%				104/107 97%				103/106 97%

